Bluebird Bio's (BLUE) Abecma Becomes the First BCMA Targeting CAR-T Therapy to Reach the Market - Stifel

March 29, 2021 7:05 AM EDT
Get Alerts BLUE Hot Sheet
Price: $29.67 +1.57%

Rating Summary:
    15 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 6 | New: 2
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Benjamin J. Burnett reiterated a Hold rating and $31.00 price target on bluebird bio (NASDAQ: BLUE) after the company won FDA approval for Abecma (ide-cel), becoming the first BCMA targeting
CAR-T therapy to reach the market.

The analyst stated "We were surprised by a few aspects of the label: Abecma was approved for 5L+, versus our expectation of 4L+, and HLH was included as a black box warning. However, after reflecting on these points with a KOL (tertiary care physician who leads CAR-T efforts at his institution), we think neither will significantly impact adoption. He noted that though this is the first CAR-T label where we've seen HLH listed as a black box warning, the syndrome itself is not specific to Abecma and occurs with other approved CART's (such as Yescarata). For the stock, we think approval was mostly anticipated, though given recent regulatory setbacks with LentiGlobin and the early challenges of submitting the Abecma BLA, we expect shares to be up small. Our target price remains unchanged at $31/share".

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $32.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Stifel, FDA